

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

## A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity?

Maher A. Sughayer<sup>a\*</sup>, Asem Mansour<sup>b</sup>, Abeer Al Nuirat<sup>a</sup>, Lina Souan<sup>a</sup>, Rashid Abdel-Razeq<sup>a</sup>, Mahmoud Siag<sup>a</sup>

<sup>a</sup>Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan

<sup>b</sup>Department of radiology, and CEO, King Hussein Cancer Center

\* Corresponding Author: 202 Q, Rania St.

Amman, Jordan

msughayer@khcc.jo



41 In a previous issue of International Journal of Infectious Diseases (Sughayer et al, 2021), we  
42 reported a dramatic rise in seroprevalence rates of SARS-CoV-2 in healthy blood donors from  
43 0% during the months of January to September 2020 up to 27.4% in late January- early  
44 February 2021, just after the end of the first wave of COVID-19 in Jordan. None of the blood  
45 donors had received any vaccination by that time.

46 A second wave of COVID-19 infection started in March and ended in May, 2021. Also a national  
47 vaccination campaign has been ongoing since January of this year. To date approximately 3  
48 million adults have received at least one dose of the COVID-19 vaccine and around 770,000  
49 were PCR-confirmed COVID-19 infected (Ministry of Health-Jordan, 2021). Currently 90% of the  
50 new cases are caused by the delta variant.

51  
52 To assess the impact of the second wave of COVID-19 and the vaccination on the  
53 seroprevalence of SARS-CoV-2 we tested 536 healthy blood donors in June -2021 using a  
54 commercially available quantitative assay for the total antibodies including IgG against the  
55 spike (S) protein receptor binding domain (RBD) of the SARS-CoV-2: the Elecsys Anti-SARS-CoV-  
56 2 S (Roche Diagnostics, Mannheim, Germany). This assay uses a recombinant protein  
57 representing the RBD of the S antigen in a double-antigen sandwich assay format, which favors  
58 detection of high affinity antibodies against SARS-CoV-2. It has a sensitivity of 98.8 % (95 % CI:  
59 98.1 – 99.3 %) and a specificity of 100 % (95 % CI: 99.7 – 100 %).

60 The demographics of the blood donors and the results of the serological assay are shown in the  
61 table.

62

Category		Seropositive donors 399 of 536	Seronegative donors 137 of 536	p-value	Crud Prevalence rate
<b>Number of donors</b>		399 (%)	137 (%)		74.4%
<b>Male</b>		361 (90.5%)	119 (86.9%)	0.23	75.2%
<b>Female</b>		38 (9.5%)	18 (13.1%)		67.9%
<b>Age (yr)</b>	<b>18-30</b>	204 (51.1%)	85(62.1%)	0.06	70.6%
	<b>31-40</b>	115(28.8%)	29(21.2%)		79.9%
	<b>41-50</b>	52(13.0%)	19(13.9%)		73.2%
	<b>51-68</b>	28(7.1%)	4(2.9%)		87.5 %
<b>Blood group &amp; RH:</b>	<b>O</b>	143(35.8%)	50(36.5%)	0.12	74.1%
	<b>A</b>	145(36.3%)	62(45.3%)		70.0%
	<b>B</b>	84(21.1%)	18(13.1%)		82.4%
	<b>AB</b>	27(6.8%)	7(5.1%)		79.4%
<b>RH positive</b>		351(88.0%)	122(89.1%)	0.73	74.2%
<b>RH Negative</b>		48(12.0%)	15(10.9%)		76.2%
<b>Residential Location</b>	<b>North</b>	67(16.8%)	26(18.9%)	0.48	72.0%
	<b>Center including Amman</b>	319(79.9%)	109(79.6%)		74.5%
	<b>South</b>	13(3.3%)	2(1.5%)		86.7%
<b>Covid-19</b>	<b>Confirmed Past infection</b>	69(17.3%)	2(1.5%)	<0.00001	
	<b>Vaccinated</b>	245(61.4%)	33(24.1%)	<0.00001	
	<b>No/negative PCR</b>	330(82.7%)	135(98.5%)	<0.00001	
	<b>No infection/No vaccine</b>	123(30.8%)	103(75.2%)	<0.00001	
<b>Confirmed past infection/No vaccine</b>		31 (7.8%)	1 (0.7%)	0.0027	

63

64

65

66 As seen in the table 399 (74.4%) of the donors were found to be seropositive of whom 245  
67 (61.4%) have received at least one dose of the vaccine and 69 (17.3%) were previously infected.  
68 Some of the previously infected have received also at least one dose of the vaccine. A  
69 substantial number 123 (30.8%) of the seropositive donors were neither vaccinated nor had  
70 been previously diagnosed with the infection. Interestingly, 33 (24.1%) of the seronegative  
71 donors have received the vaccine of whom 29 received only one dose and 4 received 2 doses.  
72 While of the vaccinated seropositive donors 119 have received only one dose of the vaccine in  
73 contrast to 126 who received full vaccination.

74 The vaccines types were either Pfizer-BioNTech, Sinopharm, or Astra-Zeneca's. No significant  
75 differences were found between the seronegative and seropositive donors in terms of age, sex,  
76 blood group or residential location. However the seropositive donors were significantly more  
77 likely to have been vaccinated or previously infected. The overall at least one dose-vaccination  
78 rate in the entire group of donors is 51.9%. The one-dose vaccination rate in the targeted  
79 population of Jordan is currently approximately 45%.

80 The crude seroprevalence rate of 74.4% in this group of blood donors may indicate that the  
81 Jordanian adult community has attained a substantial rate of herd immunity. The most  
82 important question then becomes: what is the level of herd immunity needed in the case of  
83 COVID-19 to effectively prevent the transmission?

84 The minimum threshold for herd immunity is theoretically estimated to be 60-72%, however  
85 the issue is much more complicated and it may be up to 90% and even that the entire  
86 population needs to be vaccinated/revaccinated to cut the transmission (Kadkhoda, 2021;

87 Aschwanden, 2020). Therefore we believe that despite of this apparent high level of community  
88 immunity we are far from achieving the required herd immunity. Continuation of the  
89 vaccination campaign and other precautionary measures of mask-wearing and social distancing  
90 are still need to be adhered to.

91

92

93 The Authors declare no conflict of interest.

94 No funding was received.

95 The IRB at King Hussein Cancer Center approved the study

96

97

## 98 **References:**

99

100 Aschwanden, C., 2020. The false promise of herd immunity for COVID-19. *Nature* 587, 26–28.

101 <https://doi.org/10.1038/d41586-020-02948-4>

102 Kadkhoda, K., 2021. Herd Immunity to COVID-19: Alluring and Elusive. *American Journal of*

103 *Clinical Pathology* 155, 471–472. <https://doi.org/10.1093/ajcp/aqaa272>

104 Ministry of Health, Jordan. <https://corona.moh.gov.jo/en> (accessed 2.8.2021).

105 Sughayer, M.A., Mansour, A., Al Nuirat, A., Souan, L., Ghanem, M., Siag, M., 2021. Dramatic rise

106 in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution

107 of a pandemic. *International Journal of Infectious Diseases* 107, 116–120.